MYCELEX-7 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MYCELEX-7 COMBINATION PACK (MYCELEX-7 COMBINATION PACK).
Clotrimazole, an imidazole antifungal, inhibits cytochrome P450 14α-demethylase (CYP51), thereby blocking ergosterol synthesis in fungal cell membranes, increasing membrane permeability and causing cell death. Miconazole, also an imidazole, similarly inhibits CYP51, disrupting ergosterol synthesis.
| Metabolism | Clotrimazole is metabolized in the liver primarily via oxidation and glucuronidation, involving CYP3A4. Miconazole is metabolized in the liver via oxidative pathways, primarily by CYP3A4 and CYP2C9. |
| Excretion | Clotrimazole is primarily excreted via feces (approximately 65%) as metabolites and unchanged drug; renal excretion accounts for less than 1% after topical administration. Biliary excretion is negligible. |
| Half-life | Topical clotrimazole has a terminal elimination half-life of 3-6 hours; systemic absorption is minimal, so half-life is not clinically relevant for local effects. |
| Protein binding | Clotrimazole is 97-99% protein-bound (primarily to albumin). |
| Volume of Distribution | Volume of distribution is not well-characterized due to minimal systemic absorption; estimated Vd is approximately 0.1 L/kg after topical application, reflecting limited distribution. |
| Bioavailability | Bioavailability: Vaginal tablet—3-10% absorbed systemically; topical cream/solution—<0.5% absorbed; negligible systemic exposure after topical use. |
| Onset of Action | Onset: Vaginal tablet—relief of symptoms typically begins within 24 hours; topical cream or solution—local symptomatic improvement within 2-4 days. |
| Duration of Action | Duration: Vaginal tablet—sustained release over 24-72 hours; topical cream/solution—effects last for the duration of application, typically 7 days for candidal infections. |
| Molecular Weight | 344.84 |
Clotrimazole vaginal cream 1%: one applicatorful (approximately 5 g) intravaginally at bedtime for 7 consecutive days. Clotrimazole vaginal tablets 100 mg: one tablet intravaginally at bedtime for 7 consecutive days.
| Dosage form | CREAM, TABLET |
| Renal impairment | No dose adjustment required for renal impairment. Systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for hepatic impairment. Systemic absorption is minimal. |
| Pediatric use | Not recommended for children under 12 years of age. For children 12 years and older, same as adult dosing. |
| Geriatric use | No specific dose adjustment; use same as adult dosing. Consider potential for decreased renal/hepatic function but no adjustment necessary due to minimal systemic absorption. |
| 1st trimester | Topical clotrimazole is generally considered safe in the first trimester; limited systemic absorption. However, avoid intravaginal application during first trimester unless clearly necessary due to potential risk (theoretical, minimal data). |
| 2nd trimester | Considered safe in second trimester; topical and intravaginal use acceptable when indicated. |
| 3rd trimester | Considered safe in third trimester; topical and intravaginal use acceptable. |
Clinical note
Comprehensive clinical and safety monograph for MYCELEX-7 COMBINATION PACK (MYCELEX-7 COMBINATION PACK).
| Placental transfer | Negligible placental transfer due to low systemic absorption after topical/intravaginal administration. Clotrimazole is highly protein-bound and has low lipid solubility. |
| Breastfeeding | Minimal systemic absorption after topical/intravaginal use; considered compatible with breastfeeding. Avoid application to breast area to prevent infant ingestion. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to clotrimazole or any component of the formulation
| Precautions | For intravaginal use only; not for ophthalmic or oral use., Discontinue if irritation or hypersensitivity occurs., Use during pregnancy only if clearly needed (pregnancy category C)., Instruct patient to consult physician if symptoms persist beyond 7 days or recur within 2 months., Possible interaction with warfarin (miconazole component may enhance anticoagulant effect). |
| Food/Dietary | No significant food interactions for topical/vaginal use. Avoid alcohol if using oral azoles (not applicable here). |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Clotrimazole, the active ingredient in MYCELEX-7 COMBINATION PACK, is classified as FDA Pregnancy Category C. Systemic absorption after vaginal application is minimal (approximately 3-10%). Animal studies with high subcutaneous doses have shown embryotoxicity; however, no teratogenic effects have been observed in humans with standard topical use. There is no evidence of fetal risk in the first trimester based on large epidemiological studies. Second and third trimesters: no known risk when used as directed. |
| Fetal Monitoring | No specific monitoring is required beyond standard prenatal care. For recurrent symptoms or treatment failure, confirm diagnosis and rule out other pathogens. Fetal monitoring is not indicated. |
| Fertility Effects | No known adverse effects on fertility in women. Animal studies do not indicate impaired fertility. Clotrimazole is used for vulvovaginal candidiasis and does not impact ovarian function or conception. |
| Mycelex-7 Combination Pack contains clotrimazole (antifungal) and a topical corticosteroid (clotrimazole 1% + betamethasone 0.05%?). Actually, standard Mycelex-7 is clotrimazole 1% vaginal cream, but 'Combination Pack' may include a vaginal cream and external cream; verify product. For vulvovaginal candidiasis: use intravaginally at bedtime for 7 days; external cream for symptomatic relief. Avoid use in patients with hypersensitivity to imidazoles. Caution in diabetes, immunocompromised. If no improvement in 3 days, reassess. |
| Patient Advice | Apply the vaginal cream at bedtime for 7 consecutive nights, even if symptoms improve. · Do not use tampons, douches, or have vaginal intercourse during treatment. · If you are pregnant, consult your doctor before use. · Stop use and consult doctor if irritation, rash, or worsening occurs. · For external cream, apply sparingly to affected area not more than twice daily. · Complete full course to prevent recurrence. |